THESEUS PHARMACEUTICALS, INC. Operating Cash Flow
THESEUS PHARMACEUTICALS, INC. reported Operating Cash Flow of -$39.70 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2023-11-17
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2023-09-30 was -$11.03M.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2023-06-30 was -$10.04M.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2023-03-31 was -$18.63M.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2022-12-31 was -$9.94M.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$32.95M.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2021 was -$27.19M.
- THESEUS PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2020 was -$4.85M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$11.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | -$21.07M derived: sum of 2 quarters · filed 2023-11-17 | -$39.70M 10-Q · filed 2023-11-17 | -$49.63M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | -$10.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$28.67M 10-Q · filed 2023-08-10 | -$38.61M derived: sum of 3 quarters · filed 2023-08-10 | -$45.83M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-03-31 | -$18.63M 10-Q · filed 2023-05-11 | -$28.57M derived: sum of 2 quarters · filed 2023-05-11 | -$35.79M derived: sum of 3 quarters · filed 2023-11-17 | -$43.89M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-12-31 | -$9.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$17.16M derived: sum of 2 quarters · filed 2023-11-17 | -$25.26M derived: sum of 3 quarters · filed 2023-11-17 | -$32.95M 10-K · filed 2023-03-09 |
| 2022-09-30 | -$7.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | -$15.32M derived: sum of 2 quarters · filed 2023-11-17 | -$23.01M 10-Q · filed 2023-11-17 | -$32.92M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | -$8.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$15.78M 10-Q · filed 2023-08-10 | -$25.70M derived: sum of 3 quarters · filed 2023-08-10 | -$31.02M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$7.68M 10-Q · filed 2023-05-11 | -$17.60M derived: sum of 2 quarters · filed 2023-05-11 | -$22.92M derived: sum of 3 quarters · filed 2023-05-11 | -$29.68M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$9.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$15.23M derived: sum of 2 quarters · filed 2023-03-09 | -$21.99M derived: sum of 3 quarters · filed 2023-03-09 | -$27.19M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$5.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$12.08M derived: sum of 2 quarters · filed 2022-11-03 | -$17.28M 10-Q · filed 2022-11-03 | -$18.52M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$6.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$11.96M 10-Q · filed 2022-08-11 | -$13.20M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$5.20M 10-Q · filed 2022-05-12 | -$6.44M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$4.85M 10-K · filed 2022-03-10 | ||
| 2020-09-30 | -$3.61M 10-Q · filed 2021-11-15 |